Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
fruquintinib + sintilimab versus axitinib or everolimus as second-line treatment for advanced renal cell carcinoma
CTR20222029Phase 3Completed
- Sponsor
- HUTCHMED
- Start
- Oct 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fruquintinib, sintilimab, axitinib and everolimus in renal cell carcinoma (RCC) (4 arms), sponsored by HUTCHMED. Primary endpoints: Progression-free survival and Objective response rate. Started Oct 2022; status: completed.
02
Drugs
fruquintinibsintilimabaxitinibeverolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on CTR20222029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222029.